DarDoc launches truesight beta AI layer inside Lifestyle Rx platform
DarDoc, the UAE-based home healthcare platform, has launched truesight in public beta as an embedded intelligence layer inside its Lifestyle Rx digital subscription clinic. The tool is positioned by the company as a proactive contextual memory system: rather than waiting for patients to report changes, it reads accumulated data across a patient's full history and surfaces a single daily insight before the patient thinks to raise it.
The product draws on a broad range of inputs gathered through the Lifestyle Rx platform: intake forms, consult notes, prescription and dose change records, confirmed medication intake, weight and activity data, free-text notes written by patients in Arabic or English, and app-usage patterns including what a patient consistently ignores. From that corpus, truesight maintains a running picture of each patient's stable facts, prior disclosures and previously declined recommendations.
How the system works
Rather than committing to a single explanation when data shifts, the system holds multiple hypotheses simultaneously, each weighted against supporting and contradicting evidence, before surfacing the one it deems most relevant. When new data weakens an earlier observation, the system retracts it explicitly rather than leaving it to stand unchallenged. DarDoc says this epistemic conservatism is deliberate: the product is not designed to diagnose, prescribe or treat, and clinical decisions remain with licensed physicians.
The company illustrated the approach with a beta-phase example in which a patient's weight and meal patterns changed over a week. Instead of logging the deviation as non-adherence, truesight asked the patient directly whether circumstances had changed. The patient explained they were staying in hospital with a family member, and the context was passed to the care team rather than recorded as a compliance gap.
"Healthcare has traditionally focused on the treatment itself, but outcomes are shaped by what happens between appointments," said Keswin Suresh, co-founder of DarDoc. "We built truesight to be the companion layer that carries each patient's context forward and helps them stay on track toward the outcome they came to us for."
Market context and competitive landscape
The product sits in a crowded but still-maturing corner of digital health. Patient engagement and adherence platforms have proliferated in the United States and Europe, where companies including Wellth, Memora Health and a range of EHR-integrated tools compete to close the between-appointment gap. In the Gulf Cooperation Council region, the market is less consolidated, and DarDoc is making an early positioning claim: the company says it believes truesight is the first system of its kind in the UAE, though that claim is unverifiable against a named third-party benchmark.
A second phase is planned shortly after the beta period concludes. That iteration is described as extending into the clinical appointment itself, adding real-time transcription of physician-patient conversations, with patient consent obtained at onboarding. Lab test data will also be integrated in the second phase, connecting biomarker history to the conversation record.
The beta is currently live for iOS users on the Lifestyle Rx platform; Android availability is expected to follow. DarDoc is not disclosing enrolment numbers. The company, founded in 2021 and an alumnus of the UAE Ministry of Finance's Mohammed Bin Rashid Innovation Fund accelerator, holds Digital Clinic, Home Healthcare and Pharmacy licences from the Dubai Health Authority, as well as Department of Health accreditation in Abu Dhabi. The company stated explicitly that truesight is not connected to its previously announced partnership with Novo Nordisk.